Rectal temperature and heat transfer dynamics in the eye, face, and breast of broiler chickens exposed to moderate heat stress.

This study aimed to characterize body temperature in finishing broiler chickens and to explore heat transfer dynamics under thermoneutral (TN) and heat stress (HS) conditions. To achieve this, 900 Ross 308 chicks were divided into TN and HS groups, with the HS group subjected to cyclical heat stress (30°C, 45 % RH) from day 28 to day 33 post-hatch. Rectal temperature (T) and skin temperature (T) at the face (T), eye (T), and breast (T) were measured.

The potential of in ovo-fed amino acids to alleviate the effects of heat stress on broiler chickens: effect on performance, body temperature, and oxidative status during the finisher phase.

The aim of the current study was to investigate the potential of in ovo-fed amino acids (AA) to reduce the effects of heat stress on finishing broiler chickens. To achieve this, a total of 1,400 fertile hatching eggs were randomly distributed into 5 groups (n = 280/group) and injected with one of the following in ovo treatments on embryonic day 18: 52 µL of sterile diluent/egg (CTRL), CTRL + 1.0 mg of L-Leucine (T1), CTRL + 0.

Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study.

Background: The combination of a taxane with trastuzumab and pertuzumab is standard of care for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. The combination of vinorelbine with trastuzumab and pertuzumab showed anti-tumor activity in a phase 2 trial.

Patients And Methods: The databases of two tertiary medical centers were retrospectively searched for patients with HER2-positive metastatic breast cancer who underwent first-line treatment in 2013-2019 with a taxane or vinorelbine in combination with trastuzumab and pertuzumab.

A real-world analysis of cancer drug wastage due to oversized vials.

Objectives: A recent theoretical economic model suggested that oversized vials of cancer drugs lead to $1.8 billion of drug wastage annually in the United States. It is currently unknown how precisely this theoretical model is consistent with the real world.